Mounjaro
Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist indicated as an adjunct to diet and exercise for glycemic control in adults with type 2 diabetes.
Brief glance
Mounjaro is a branded drug product manufactured by Eli Lilly. Its active substance is Tirzepatide. The linked substance is commonly grouped under “Weight Loss” as a primary outcome. FDA status: Approved. First FDA approval on record: May 2022. It is not currently flagged on our shortage list.
| Phase | Days | Dosage | Frequency |
|---|---|---|---|
| titration | 1 – 28 | 2.5 mg | Every 7 days |
| maintenance | 29+ | 5 mg | Every 7 days |
Follows prescribing guidance issued for this product. Not medical advice — consult your healthcare professional before starting, adjusting, or stopping any medication.
Overview
Mounjaro (tirzepatide) is an injectable GIP and GLP-1 receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The medication works by targeting two gut hormones to increase insulin release in response to elevated blood sugar, reduce appetite, and slow digestion, thereby lowering blood glucose levels without significantly increasing the risk of hypoglycemia. Clinical studies demonstrated that Mounjaro reduced HbA1c by up to 2.6 percentage points when used alone or added to existing diabetes treatments, and also produced clinically meaningful weight loss in patients with obesity or overweight conditions.
Mounjaro is a prescription injectable medication containing the active substance tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. It is indicated as an adjunct to diet and exercise for improving glycemic control in adults with type 2 diabetes mellitus, either as monotherapy when metformin is inappropriate or in combination with other antidiabetic therapies. Tirzepatide enhances insulin secretion from the pancreas in response to meals, suppresses glucagon release, slows gastric emptying, and reduces appetite, thereby lowering blood glucose levels and promoting weight loss without substantially increasing hypoglycemia risk. Clinical studies demonstrate significant reductions in HbA1c (up to 2.6 percentage points) and body weight in patients with type 2 diabetes.
Benefits
Mounjaro (tirzepatide) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, achieving significant reductions in A1c levels and enabling some patients to reach non-diabetic ranges.1,2,3,4 It promotes substantial weight loss through dual agonism of GLP-1 and GIP receptors, which suppresses appetite, enhances satiety, slows gastric emptying, and improves insulin sensitivity, outperforming single-agonist therapies in clinical trials.1,5,6 Additional clinically observed effects include lowered blood pressure, improved lipid profiles, and better metabolic parameters, though cardiovascular outcome data remain pending from ongoing studies.1,5,6,7
Side effects
Common side effects of Mounjaro include nausea, diarrhea, vomiting, constipation, decreased appetite, indigestion, abdominal pain, burping, flatulence, injection site reactions, and fatigue, which often occur during dose escalation and tend to improve over time.8,9,10 Serious adverse effects may encompass pancreatitis, gallbladder disease, acute kidney injury from dehydration due to gastrointestinal issues, severe hypoglycemia when combined with other antidiabetic agents, vision changes, and a potential risk of thyroid C-cell tumors.8,9,10 Allergic reactions, ranging from mild rash to anaphylaxis with symptoms like swelling, breathing difficulty, or rapid heartbeat, have been reported rarely.8,10 Safety considerations include monitoring for severe abdominal pain lasting over several hours, persistent vomiting, jaundice, or signs of low blood sugar such as confusion or sweating, and discontinuing use if pancreatitis or allergic reactions are suspected while seeking immediate medical attention.8,10,11 Patients with pre-existing kidney issues require close monitoring due to dehydration risks.10
Mechanisms of action
Mounjaro (tirzepatide) is a dual agonist that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.12,13,14,15 At the molecular level, it binds to these receptors on pancreatic beta cells to stimulate glucose-dependent insulin secretion and enhances insulin sensitivity while suppressing glucagon release from alpha cells, thereby reducing hepatic glucose production.12,15,16 Physiologically, it slows gastric emptying to delay nutrient absorption and promotes satiety by acting on hypothalamic receptors that regulate appetite and food intake.12,13,14,16 These combined actions lower fasting and postprandial blood glucose levels.12,14